Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663330 | 1.00 | CYP2A6 (0.56) | CYP2A6ADORA2AADORA1L3MBTL1KMT2A | |
| SCHEMBL12679716 | 0.85 | ALDH1A1 (0.52) | ADORA2AADORA1L3MBTL1KMT2ALMNA | |
| SCHEMBL26553310 | 0.80 | ADORA2A (0.48) | CYP2A6ADORA2AADORA1L3MBTL1KMT2A | |
| SCHEMBL25864403 | 0.80 | ADORA2A (0.45) | ADORA2AADORA1L3MBTL1KMT2ALMNA | |
| SCHEMBL20740876 | 0.79 | ALDH1A1 (0.47) | ADORA2AADORA1L3MBTL1KMT2ALMNA | |
| SCHEMBL29029145 | 0.78 | CYP2A6 (0.43) | CYP2A6ADORA2AADORA1L3MBTL1KMT2A | |
| SCHEMBL4958212 | 0.78 | ALDH1A1 (0.53) | ADORA2AADORA1L3MBTL1KMT2ALMNA | |
| Dichlobenil SCHEMBL1701380 | 0.78 | ALDH1A1 (0.55) | CYP2A6L3MBTL1KMT2ALMNAHPGD | |
| Dichlobenil SCHEMBL55606 | 0.78 | ALDH1A1 (0.55) | CYP2A6L3MBTL1KMT2ALMNAHPGD | |
| SCHEMBL769515 | 0.78 | SMN1; SMN2 (0.51) | ADORA2AADORA1L3MBTL1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110333619-A | A kind of polymer dispersed liquid crystal film and its manufacturing method based on macromolecule transparent conductive substrate | 烟台如水光电科技有限公司 | 2019-10-15 | — | — | CN | claimed |
| CN-109665990-A | A kind of synthesis technology of Boscalid | 安徽赛乐普制药有限公司 | 2019-04-23 | — | — | CN | claimed |
| CN-106398715-A | High temperature liquid crystal composition, high temperature polymer dispersed liquid crystal composition and high temperature polymer dispersed liquid crystal membrane | 中节能万润股份有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-106117084-A | A kind of big production method of 4 chlorine 2 ' cyanobiphenyls | 江苏中旗作物保护股份有限公司 | 2016-11-16 | — | — | CN | claimed |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-4212511-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
| CN-111004149-B | Method for preparing polyfluorobenzonitrile by catalytic fluorination of polychlorinated benzonitrile | 大连奇凯医药科技有限公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022052926-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 广州再极医药科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
| CN-111004149-A | Method for preparing polyfluorobenzonitrile by catalytic fluorination of polychlorinated benzonitrile | 大连奇凯医药科技有限公司 | 2020-04-14 | — | — | CN | disclosed |
| CN-110333619-A | A kind of polymer dispersed liquid crystal film and its manufacturing method based on macromolecule transparent conductive substrate | 烟台如水光电科技有限公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-109665990-A | A kind of synthesis technology of Boscalid | 安徽赛乐普制药有限公司 | 2019-04-23 | — | — | CN | disclosed |
| CN-106398715-A | High temperature liquid crystal composition, high temperature polymer dispersed liquid crystal composition and high temperature polymer dispersed liquid crystal membrane | 中节能万润股份有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-106398715-A | High temperature liquid crystal composition, high temperature polymer dispersed liquid crystal composition and high temperature polymer dispersed liquid crystal membrane | 中节能万润股份有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-106117084-A | A kind of big production method of 4 chlorine 2 ' cyanobiphenyls | 江苏中旗作物保护股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-102203093-B | Aminotriazolopyridines and their use as kinase inhibitors | SIGNAL PHARM LLC | 2015-05-13 | — | — | CN | disclosed |
| CN-102070465-B | Method for preparing phenylaniline | CHANGCHUN APPLIED CHEMISTRY | 2013-12-18 | — | — | CN | disclosed |
| CN-102070465-A | Method for preparing phenylaniline | CHANGCHUN APPLIED CHEMISTRY | 2011-05-25 | — | — | CN | disclosed |
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | CYP2A6 540/4885ADORA2A 3090/4885ADORA1 2168/4885 |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | PDCD1, CD274, PDCD1LG2 | CYP2A6 1115/4885ADORA2A 4579/4885ADORA1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.